Avita Medical Inc.

RCEL

$10.94

+1.67%

2026-09-03 16:00:00 EDT+$0.18

Healthcare

Medical - Devices

NASDAQ

Active Trading

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European ...

Price Action of RCEL

$10.94

+1.67%+$0.18

High—

Low—

52W High0.6%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

AVITA Medical, Inc. (NASDAQ: RCEL) is a leading therapeutic acute wound care company headquartered in Valencia, California. The company specializes in regenerative medicine, developing innovative products that harness the body's own healing capabilities to address unmet medical needs in skin restoration. Its flagship product, the RECELL System, is a cell ...AVITA Medical, Inc. (NASDAQ: RCEL) is a leading therapeutic acute wound care company headquartered in Valencia, California. The company specializes in regenerative medicine, developing innovative products that harness the body's own healing capabilities to address unmet medical needs in skin restoration. Its flagship product, the RECELL System, is a cell harvesting device approved for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. The company offers a range of devices, including RECELL, RECELL GO, and RECELL GO mini, which vary in the treatment area they can cover, from up to 480 cm² to 1,920 cm². Additionally, AVITA distributes PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix. The company serves hospitals, treatment centers, and distributors primarily in the United States, Japan, the European Union, Australia, and the United Kingdom. As of the latest TTM data, AVITA Medical has a market cap of approximately $203.7 million, with a gross profit margin of 81.6% but currently operates at a net loss, reporting a net profit margin of -57%. The company invests heavily in research and development, with R&D expenses representing about 26.6% of revenue. The CEO, Cary G. Vance, has over 30 years of healthcare industry experience and has served on the board since 2023. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. Its parent company, AVITA Australia, was founded in December 1992, but the company restructured under the 'Avita Medical' brand in 2008. With 226 full-time employees, AVITA Medical continues to innovate in the field of wound care, aiming to optimize healing and accelerate patient recovery. The company's commitment to advancing skin restoration technologies is evident in its product pipeline and its strategic focus on commercial expansion and clinical development.ExpandCollapse

Founded

2008

Employees

226

CEO

Cary G. Vance

Full Name

Avita Medical Inc.

Sector

Healthcare

Industry

Medical - Devices

ROE

231.87%

Market Cap

$0.27B

Current Ratio

0.41

WACC

13.04%

ROIC

152.37%

Contact Information

https://avitamedical.com

661 367 9170

28159 Avenue Stanford, Valencia, CA 91355

Key Metrics of RCEL

Snapshot

Latest / TTM · 6 periods

Market Cap

$271.78M

ROCE

168.2%

EV / EBITDA

-9.04x

-508.5% YoY

FCF Yield

-8.7%

+25.6% YoY

Cash Conversion Cycle

17.9d

Current Ratio

0.41

Quick take

TTM —

Current ratio below 1.0

Negative working capital

Financial Highlights of RCEL

Profitability trend

Latest / TTM · 6 periods

Gross Margin

81.6%

Net Margin

-57.0%

P/E Ratio

-7.54x

n/a

Debt / Equity

-1.74

n/a

Current Ratio

0.41

Dividend Yield

0.0%

Understanding

TTM —

Current ratio below 1.0

Interest coverage is weak

Calendar of RCEL

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.24 · Revenue $22.35M · 2 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.19 · Revenue $24.00M · 4 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.95 · Revenue $87.50M · 3 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.19 · Revenue $25.30M · 1 analysts

Recent history

Aug 6, 2026
Q2 FY2026 · Results reported
EPS $-0.25 · Revenue $21.70M
View filing
May 14, 2026
Q1 FY2026 · Results reported
EPS $-0.36 · Revenue $19.25M
View filing
Feb 12, 2026
FY2025 · Annual results
EPS $-1.74 · Revenue $71.61M
View filing
Nov 6, 2025
Q3 FY2025 · Results reported
EPS $-0.46 · Revenue $17.06M
View filing
Aug 8, 2025
Q2 FY2025 · Results reported
EPS $-0.38 · Revenue $18.42M
View filing
May 8, 2025
Q1 FY2025 · Results reported
EPS $-0.53 · Revenue $18.51M
View filing

Financial Statements of RCEL

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$71.6M	+11.5%	+12.7%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-48.6M	+21.4%	+27.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+82.1%	-4.3%	+0.2%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-59.4%	+32.6%	+30.9%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-67.8%	+29.5%	+35.9%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-32.9M	+43.5%	+64.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-46.0%	+49.3%	+68.4%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	-276.6%	-127.1%	+16.2%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	0.57x	-80.0%	-12.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$56.4M	-29.3%	-7.3%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.74 vs -1.80	+3.3%	-0.25 vs -0.24	-4.4%
Revenue Surprise	$71.6M vs $71.5M	+0.2%	$21.7M vs $22.4M	-2.9%

Insider Transactions of RCEL

Acquisitions (A)

Since May 20, 2026

Disposals (D)

Since May 20, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jun 12, 2026	O'Toole David D	officer: CFO	Common Stock	A	2,000	$3.97
Jun 12, 2026	O'Toole David D	officer: CFO	Common Stock	A	2,000	$3.97
Jun 9, 2026	Woody Joseph Fralin	director	Common Stock	A	5,200	$4.00
Jun 9, 2026	Woody Joseph Fralin	director	Common Stock	A	5,000	$4.18
Jun 9, 2026	Woody Joseph Fralin	director	Common Stock	A	5,000	$4.20

Earnings Call Transcript of RCEL

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good day, and thank you for standing by. Welcome to the AVITA Medical, Inc. Second quarter 26 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Ben Atkins, Vice President of Investor Relations and Corporate Communications. Please go ahead. Ben Atkins: Thank you, operator. Welcome to AVITA Medical's second quarter 26 earnings call. Joining me on today's call are Carrie Vance, president and chief executive officer and David O'Toole, Chief Financial Officer. Today's earnings release and presentation are available on our website at www.avitamedical.com under the Investor Relations section. Before we begin, I would like to remind you that this call includes forward looking statements within the meaning of the Private Securities Litigation Reform Act of 2000. These statements are neither promises nor guarantees and involve known and unknown risks and uncertainties. That could cause actual results to differ materially from any expectations expressed or implied by the forward looking statements. Please review our most recent filings with the SEC for comprehensive descriptions of the risk factors. Any forward looking statements provided during this call are based on expectations as of today. I will now turn the call over to Carrie. Cary G. Vance: Good afternoon in the US, and good morning in Australia. Thank you for joining us. As you saw in our press release today, we delivered strong revenue growth in the second quarter of $21.7 million, up 18% year over year and 13% sequentially. As AVITA continues to expand in the US, and build its presence in key international markets, Our results reflect the growing utility of our acute wound care portfolio. Led by RECELL and supported by Cohealyx and PermeaDerm. In the US, ReCell generated $8.5 million in revenue during the second quarter. Growing 13% sequentially from the prior quarter. This growth reflected physician utilization following physician reimbursement stabilization together with increasing adoption of RECELL GO Mini. Which continues expanding use in smaller wounds. I will add a little more color on ReCell later in my remarks. Internationally, revenue from RECELL increased 26% sequentially over the first quarter. Continue to commercialize RECELL GO Following Regulatory Authorizations in Europe, the UK, Australia, and New Zealand. As adoption builds, clinicians are also beginning to share their early clinical experience. During the quarter, the British Burn Association annual meeting featured the first UK clinical experience with RECELL GO. Reporting …

Leadership Team of RCEL

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Cary G. Vance	Chief Executive Officer, President & Executive Director	AUD 891,974	Male	1966	Active
David O'Toole	Chief Financial Officer	AUD 638,256	Male	1959	Active
Nicole Linda Kelsey	Chief Legal & Compliance Officer, Corporate Secretary and Interim SVP of Human Resources	AUD 573,061	Female	1967	Active
Katie Bush	Senior Vice President of Scientific & Medical Affairs	—	—	—	Active
Niraj Doshi	Senior Vice President of Global Operations	—	—	—	Active
Robin VanDenburgh	Senior Vice President of U.S. Commercial Sales	—	Female	—	Active
Ben Atkins	Vice President of Investor Relations & Corporate Communications	—	Male	—	Active
Debbie Garner	Senior Vice President of Global Marketing & Strategy	—	Female	—	Active
Jessica Ekeberg	Director of Investor Relations	—	Female	—	Active
Ron Lagerquist	Senior Vice President of Quality Assurance & Regulatory Affairs	—	Male	—	Active

Recent News of RCEL

Seeking Alpha8/18/2026Neutral

AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript

GlobeNewsWire8/18/2026Neutral

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

AVITA Medical's PermeaDerm study shows 70% lower product cost than allograft, with comparable clinical outcomes and a 96% reduction in preparation time.

MarketBeat8/16/2026Neutral

Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%

Avita Medical NASDAQ: RCEL reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from $19.3 million in the first quarter and 18% from $18.4 million a year earlier, as the wound-care company cited growth across its product portfolio and in U.S. and international markets.

MarketBeat8/16/2026Neutral

Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds

Avita Medical NASDAQ: RCEL expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025, President and CEO Cary Vance said at the Canaccord 46th Annual Boston Growth Conference.

Seeking Alpha8/12/2026Neutral

AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript

Historical Employee Count of RCEL

Current

226

Change

-13.08%

Minimum

126

Maximum

260

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	226	10-K	Feb 12, 2026	View
Dec 31, 2024	260	10-K	Feb 13, 2025	View
Dec 31, 2023	207	10-K	Feb 22, 2024	View
Dec 31, 2022	126	10-K	Feb 23, 2023	View

Related stocksMedical - Devices

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Avita Medical Inc.